These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 17149608)

  • 21. Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
    Bao PQ; Ramanathan RK; Krasinkas A; Bahary N; Lembersky BC; Bartlett DL; Hughes SJ; Lee KK; Moser AJ; Zeh HJ
    Ann Surg Oncol; 2011 Apr; 18(4):1122-9. PubMed ID: 21104328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
    Iannitti D; Dipetrillo T; Akerman P; Barnett JM; Maia-Acuna C; Cruff D; Miner T; Martel D; Cioffi W; Remis M; Kennedy T; Safran H
    Am J Clin Oncol; 2005 Dec; 28(6):570-5. PubMed ID: 16317266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
    Dragovich T; Burris H; Loehrer P; Von Hoff DD; Chow S; Stratton S; Green S; Obregon Y; Alvarez I; Gordon M
    Am J Clin Oncol; 2008 Apr; 31(2):157-62. PubMed ID: 18391600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
    Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
    World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
    Chiorean EG; Dragovich T; Hamm J; Langmuir VK; Kroll S; Jung DT; Colowick AB; Tidmarsh GF; Loehrer PJ
    Cancer Chemother Pharmacol; 2008 May; 61(6):1019-26. PubMed ID: 17661038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
    Cohen SJ; Zalupski MM; Modiano MR; Conkling P; Patt YZ; Davis P; Dorr RT; Boytim ML; Hersh EM
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):287-94. PubMed ID: 19855966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
    Kordes S; Pollak MN; Zwinderman AH; Mathôt RA; Weterman MJ; Beeker A; Punt CJ; Richel DJ; Wilmink JW
    Lancet Oncol; 2015 Jul; 16(7):839-47. PubMed ID: 26067687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
    Senderowicz AM; Johnson JR; Sridhara R; Zimmerman P; Justice R; Pazdur R
    Oncology (Williston Park); 2007 Dec; 21(14):1696-706; discussion 1706-9, 1712, 1715. PubMed ID: 18247017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
    Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
    Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    Kotasek D; Tebbutt N; Desai J; Welch S; Siu LL; McCoy S; Sun YN; Johnson J; Adewoye AH; Price T
    BMC Cancer; 2011 Jul; 11():313. PubMed ID: 21791058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
    Westphalen CB; Kukiolka T; Garlipp B; Hahn L; Fuchs M; Malfertheiner P; Reiser M; Kütting F; Heinemann V; Beringer A; Waldschmidt DT
    BMC Cancer; 2020 Feb; 20(1):155. PubMed ID: 32093649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
    J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
    O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
    Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
    Feliu J; Borrega P; León A; López-Gómez L; López M; Castro J; Belda-Iniesta C; Barriuso J; Martínez V; González-Barón M
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):215-21. PubMed ID: 20927525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
    Konski A; Meyer JE; Joiner M; Hall MJ; Philip P; Shields A; McSpadden E; Choi M; Adaire B; Duncan G; Meropol NJ; Cescon TP; Cohen SJ
    Radiother Oncol; 2014 Oct; 113(1):35-40. PubMed ID: 25441058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek GV; Raderer M; Hejna M; Valencak J; Miholic J; Kovats E; Lang F; Funovics J; Bareck E; Depisch D
    Br J Cancer; 1999 Aug; 80(11):1797-802. PubMed ID: 10468299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
    Cascinu S; Gasparini G; Catalano V; Silva RR; Pancera G; Morabito A; Giordani P; Gattuso D; Catalano G
    Ann Oncol; 1999 Nov; 10(11):1377-9. PubMed ID: 10631469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer].
    Cheng YJ; Bai CM; Zhang ZJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):421-3. PubMed ID: 20868602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
    Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.